JAK inhibitor

Latest news

Tag

Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial Review

This review synthesizes current evidence on ruxolitinib 1.5% cream efficacy and safety in cutaneous lichen planus, highlighting significant lesion and pruritus reduction in a pivotal phase 2 RCT, supporting its potential as a novel topical

Oct 2, 2026

Dermatology

Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial

The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases afte

Oct 24, 2025Sign in to read

Allergy & Immunology

Dual JAK and ROCK Inhibition with CPL’116: A Promising Advance for Methotrexate-Refractory Rheumatoid Arthritis

CPL’116, a novel dual JAK and ROCK inhibitor, demonstrates dose-dependent efficacy and a favorable safety profile in rheumatoid arthritis patients inadequately responsive to methotrexate, without the typical lipid or creatine kinase a

Aug 27, 2025Sign in to read